AcouSort delivers fully functional test system for automated cell handling within cell therapy


AcouSort’s collaboration with a global life science company has reached a significant milestone with the delivery of a fully functional test system for cell therapy processing. The system is operating according to the partnering company’s requirements with the intention of being integrated into a new automated cell therapy production system.

The order for the prototype was communicated in July 2023, and the unit has now been successfully delivered to the partnering company. During the installation, several researchers from the partnering company were trained on the prototype to ensure efficient execution of the evaluation phase. During this period, product design activities investigating a potential integration into their new cell therapy production system will also be performed.

Over the coming months, AcouSort will continue discussions with the partnering company to define the next steps of the collaboration. The continued collaboration constitutes a very important step towards the development of OEM components to the partnering company’s future cell therapy products and instruments.

The order for the prototype is a clear verification of the commercial potential of AcouSort’s focus on developing OEM modules for cell therapy solutions in clinical settings.

“The collaboration with the partnering company is a perfect example of our research-to-OEM strategy. By delivering a complete test system, we have taken a significant step towards our ultimate goal of securing an OEM deal with this customer. We will follow the customer’s evaluation process very closely and offer all the support they may need,” says Torsten Freltoft, AcouSort’s CEO.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854


About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.